CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation

被引：0
|
作者：
Exposito, M. J. Jimenez [1 ]
Akce, M. [2 ]
Montero Alvarez, J. L. [3 ]
Assenat, E. [4 ]
Balart, L. A. [5 ]
Baron, A. D. [6 ]
Decaens, T. [7 ]
Heurgue-Berlot, A. [8 ]
Martin, A. O. [9 ]
Paik, S. W. [10 ]
Poulart, V. [11 ]
Sehbai, A. S. [12 ]
Takemura, N. [13 ]
Yoon, J-H. [14 ]
机构：
[1] Bristol Myers Squibb, Clin Dev Oncol, Princeton, NJ USA
[2] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Hosp Univ Reina Sofia, Gastroenterol, Cordoba, Spain
[4] CHU Montpellier, Med Oncol, Hosp St Eloi, Montpellie, France
[5] Tulane Univ, Internal Med, Tulane Med Ctr, Hlth Sci Ctr, New Orleans, LA 70118 USA
[6] Calif Pacific, Med Ctr, San Francisco, CA USA
[7] CHU Grenoble Alpes, Clin Univ Hepatogastroenterol, Grenoble, France
[8] CHU Reims, Dept Hepatogastroenterol, Reims, France
[9] UAM, Digest Syst Serv, Hosp Univ La Paz, Madrid, Spain
[10] Sungkyunkwan Univ, Samsung Med Ctr, Gastroenterol, Seoul, South Korea
[11] Bristol Myers Squibb, Biostat, Braine Lalleud, Belgium
[12] Pinnacle Res Grp Llc, Hematol Oncol, Anniston, AL USA
[13] Tokyo Natl Ctr Global Hlth & Med, Gastroenterol Surg, Tokyo, Japan
[14] Seoul Natl Univ Hosp, Gastroenterol, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
783TiP
引用
收藏
页数：2
相关论文
共 50 条
  • [1] CA209-9DX: Phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation
    Exposito, M. J. Jimenez
    Akce, M.
    Alvarez, J. L. M.
    Assenat, E.
    Balart, L. A.
    Baron, A. D.
    Decaens, T.
    Heurgue-Berlot, A.
    Martin, A. O.
    Paik, S. W.
    Poulart, V.
    Sehbai, A. S.
    Shimada, M.
    Takemura, N.
    Yoon, J-H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC)
    Bruix, Jordi
    Takayama, Tadatoshi
    Mazzaferro, Vincenzo
    Chau, Gar-Yang
    Yang, Jiamei
    Kudo, Masatoshi
    Cai, Jianqiang
    Poon, Ronnie Tung-Ping
    Han, Kwang-Hyub
    Tak, Won-Young
    Lee, Han Chu
    Song, Tianqiang
    Roayaie, Sasan
    Bolondi, Luigi
    Lee, Kwan Sik
    Makuuchi, Masatoshi
    Souza, Fabricio
    Le Berre, Marie-Aude
    Meinhardt, Gerold
    Llovet, Josep M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] A Phase III, randomized, double-blind, multicenter study of adjuvant nivolumab vs placebo in patients (pts) with high-risk invasive urothelial carcinoma (UC; CheckMate 274)
    Bajorin, D.
    Galsky, M. D.
    Gschwend, J. E.
    Tomita, Y.
    Azrilevich, A.
    Witjes, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection
    Knox, J.
    Cheng, A.
    Cleary, S.
    Galle, P.
    Kokudo, N.
    Lencioni, R.
    Park, J.
    Zhou, J.
    Mann, H.
    Morgan, S.
    Liu, X.
    Chin, S.
    Vlahovic, G.
    Fan, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
    Bruix, Jordi
    Takayama, Tadatoshi
    Mazzaferro, Vincenzo
    Chau, Gar-Yang
    Yang, Jiamei
    Kudo, Masatoshi
    Cai, Jianqiang
    Poon, Ronnie T.
    Han, Kwang-Hyub
    Tak, Won Young
    Lee, Han Chu
    Song, Tianqiang
    Roayaie, Sasan
    Bolondi, Luigi
    Lee, Kwan Sik
    Makuuchi, Masatoshi
    Souza, Fabricio
    Le Berre, Marie-Aude
    Meinhardt, Gerold
    Llovet, Josep M.
    LANCET ONCOLOGY, 2015, 16 (13) : 1344 - 1354
  • [6] A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).
    Sangro, Bruno
    Harding, James J.
    Johnson, Matthew
    Palmer, Daniel H.
    Edeline, Julien
    Abou-Alfa, Ghassan K.
    Cheng, Ann-Lii
    Decaens, Thomas
    El-Khoueiry, Anthony B.
    Finn, Richard S.
    Galle, Peter R.
    Park, Joong-Won
    Yau, Thomas
    Begic, Damir
    Shen, Yun
    Neely, Jaclyn
    Sama, Ashwin Reddy
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [7] A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2
    Knox, J.
    Cheng, A.
    Cleary, S.
    Galle, P.
    Kokudo, N.
    Lencioni, P.
    Park, J.
    Zhou, J.
    Mann, H.
    Morgan, S.
    Liu, X.
    Chin, S.
    Vlahovic, G.
    Fan, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [8] A phase II study of tislelizumab (TIS) plus sitravatinib as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgical resection
    Liu, L-X.
    Peng, T.
    Liu, C.
    Wang, J.
    Zhu, G.
    Zhang, X.
    ANNALS OF ONCOLOGY, 2022, 33 : S1444 - S1444
  • [9] Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: An ongoing randomized, double-blind, phase III trial
    Cheng, Ann-Lii
    Finn, Richard S.
    Kudo, Masatoshi
    Llovet, Josep M.
    Qin, Shukui
    Le Berre, Marie-Aude
    Krissel, Heiko
    Bruix, Jordi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Imbrave050: Phase 3 Study of Adjuvant Atezolizumab plus Bevacizumab vs Active Surveillance in Patients with Hepatocellular Carcinoma at High Risk of Disease Recurrence after Resection or Ablation
    Yopp, Adam Charles
    Cheng, Ann-Lii
    Kaseb, Ahmed Omar
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2023, 237 (05) : S19 - S19
12345